Compare Ascendis Pharma A/S (ASND) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs J B Hunt Transport Services Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while J B Hunt Transport Services Inc trades at $280 (market cap $26.40B). The key difference: J B Hunt Transport Services Inc is the larger of the two by market cap, and J B Hunt Transport Services Inc pays a 0.64% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | JBHT | |
|---|---|---|
Market Cap | $17.74B | $26.40B |
Sector | Health | Industrials |
52-Week High | $277.18 | $290.07 |
52-Week Low | $163.32 | $130.65 |
Enterprise Value | $18.11B | $27.70B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
JBHT trades at $279.96, down 0.94% today, with a bullish technical outlook supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Revenue has stabilized around $12B annually, while profitability metrics show a net margin of 5.13% and ROE of 16.68%. Analyst sentiment remains positive with 57.78% buy ratings.
The stock presents a mixed valuation with elevated P/E of 43.47 but reasonable EV/EBITDA of 17.18. Near-term catalysts include Q2 earnings release on July 15, 2026. Key risks include freight market volatility and competitive pressures. The consensus price target of $273.93 suggests limited upside from current levels despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
